red-shifted bioluminescence reporters are desirable for biological imaging. We describe the development of red-shifted luciferins based on synthetic coelenterazine analogs and corresponding mutants of nanoLuc that enable bright bioluminescence. one pair in particular showed superior in vitro and in vivo sensitivity over commonly used bioluminescence reporters. We adapted this pair to develop a bioluminescence resonance-energy-based antares reporter called antares2, which offers improved signal from deep tissues.
There is enormous interest in harnessing bioluminescence for ultrasensitive bioassays, drug screening, and optical imaging [1] [2] [3] . The photon fluxes of bioluminescent reporters are determined by the quantum efficiencies and catalytic rates of bioluminescence reactions. The slow catalysis of common luciferases often results in bioluminescence emission that is several orders of magnitude lower than that of fluorescence 4 . A recent advance was the development of NanoLuc luciferase, which, when paired with a synthetic furimazine substrate ( Supplementary Fig. 1 ), generates intense blue bioluminescence much higher than that of other popular reporters 5 . However, the in vivo performance of NanoLuc is poor, particularly in deep tissues, since photons shorter than 600 nm interact strongly with mammalian tissues 6 . Because a significant portion of Firefly luciferase (FLuc) emission is longer than 600 nm, FLuc-d-luciferin remains among the top choices for deep-tissue bioluminescence imaging (BLI) 7 . Although both FLuc and d-luciferin have recently been engineered for longer wavelength emission, this desirable spectral shift is often offset by a substantially reduced total intensity 7 . Only a very few examples, such as the d-luciferin analogs CycLuc1 and AkaLumine-HCl 8, 9 , can modestly enhance FLuc bioluminescence at limited substrate concentration ranges.
Recently, NanoLuc was fused to fluorescent proteins for BRETbased reporters, and this fusion resulted in the two most red-shifted variants, Antares and ReNL 17, 18 . The absorbance of CyOFP1 in Antares overlaps better with teLuc-DTZ emission than with NanoLuc-furimazine (Supplementary Fig. 7) . By replacing NanoLuc with teLuc in Antares, we derived a BRET-based Antares2 reporter emitting 3.8 times more photons above 600 nm than Antares and 65 times more than FLuc-d-luciferin (Fig. 1b and Table 1) .
We further evaluated the bioluminescence of our new reporters using transiently transfected Human Embryonic Kidney (HEK) 293T cells. Under all conditions, the brightness of DTZ with teLuc or Antares2 was two to three orders of magnitude higher than that of FLuc-d-luciferin ( Fig. 1c-f ; Table 1 ; Supplementary Figs. 8 and 9 ). These enhancements were more dramatic than the results observed in protein assays because of the high levels of teLuc and Antares2 in live cells (Supplementary Fig. 10 ) and better cell permeability of DTZ compared with that of d-luciferin. teLuc and Antares2 also displayed improvements over NanoLuc, Antares, and ReNL ( Table 1) . teLuc emitted sustained bioluminescence with a half-life of >2 h in both intact cells and cell lysates, whereas yeLuc showed flash-type kinetics ( Supplementary Figs. 11 ). Moreover, DTZ alone yielded very little background and thus exhibited excellent signal-to-background ratios (Supplementary Fig. 12 ). Furthermore, DTZ elicited minimal cell toxicity at millimolar concentrations ( Supplementary  Fig. 13 ). In contrast, AkaLumine-HCl, furimazine, and STZ induced cell death within the tested substrate concentration range. We next explored the use of our new reporters for in vivo BLI. To compare bioluminescence at superficial sites, we subcutaneously injected HEK 293T cells expressing individual luciferases near the right dorsolateral trapezius region of unshaved BALB/c mice. For comparison, we also subcutaneously administered cells transfected with an empty vehicle to the same mice at the left dorsolateral thoracolumbar region. These injections were followed up with an additional subcutaneous luciferin injection. At a 0.1 mM substrate concentration, teLuc-DTZ was ~54-fold brighter than FLuc-d-luciferin and ~7.5-fold brighter than NanoLuc-furimazine (Fig. 2a,b and Table 1 ). The brightness of Antares2 was comparable to that of teLuc, and no background bioluminescence was observed from sites injected with vehicle-transfected cells. To further evaluate the reporters for imaging deep-tissue targets, we used hydrodynamic transfection to express luciferase genes within the internal organs of mice. After intraperitoneal injections of 0.3 µmol individual luciferin substrates, teLuc-DTZ generated ~52-fold higher emission than FLuc-d-luciferin (Fig. 2c,d and Table 1 ). With 3.3 µmol of each substrate (a dose recommended for AkaLumine-HCl 9 ), teLuc-DTZ was ~32-fold brighter than FLuc-d-luciferin and ~15-fold brighter than FLuc-AkaLumine-HCl. Moreover, teLuc with 3.3 µmol DTZ was still ~12-fold brighter than FLuc with 10 µmol d-luciferin (equivalent to the standard ~150 mg/kg FLuc imaging condition). DTZ injections into untransfected BALB/c mice did not yield any background emission (Fig. 2c) . When used for deep-tissue imaging, Antares2 shows an additional 35-90% signal increase over teLuc. Furthermore, the bioluminescence resulting from intraperitoneally injected DTZ displayed extended kinetics (Supplementary Fig. 14) , which suggests that both teLuc and Antares2 are suitable for time-lapse BLI. To further demonstrate the use of these new bioluminescent reporters to detect low-abundance targets, we intravenously injected luciferase-expressing cells into unshaved BALB/c mice. Despite the fact that ~5 × 10 5 FLuc-expressing cells were only marginally detectable, ~1 × 10 5 teLuc-or Antares2-labeled cells generated signals well above the background (Supplementary Fig. 15 ).
In summary, we have synthesized CTZ analogs with modifications at the C-8 position and re-engineered NanoLuc luciferase to catalyze these new substrates, and these analogs exhibit brighter and more red-shifted bioluminescence. Although the water solubility of these CTZ analogs is worse than that of d-luciferin, the corresponding bioluminescence reactions with low amounts of the CTZ analogs are much brighter than FLuc with d-luciferin at saturated concentrations. In particular, teLuc-DTZ is one of the brightest bioluminescent systems and shows robust performance in vitro, in cellulo, and in live mice. teLuc-DTZ will streamline a variety of applications to afford high sensitivity and reproducibility and expand the scope of BLI by allowing the use of less complicated instrumentation to track less abundant targets with higher spatiotemporal resolution. Moreover, our study demonstrates the feasibility of coengineering CTZ-consuming luciferases and substrates for improved bioluminescence. Increased detection sensitivity is not the only advantage of teLuc-DTZ. The small sizes of NanoLuc and its derivatives teLuc and yeLuc (19 kDa), compared with that of FLuc (61 kDa) and some other luciferases, facilitate their use as fusion reporters and in the assembly of viral vectors with limited packaging capacities. Moreover, NanoLuc forms a β-barrel structure that can be genetically and structurally manipulated, such as for split and fragment complementation 19 . Furthermore, the bioluminescence of NanoLuc is independent of Mg 2+ , Ca 2+ , and ATP 5 . All these factors suggest that teLuc may be an excellent scaffold for the development of bioluminescent biosensors compatible with other popular optogenetic tools 20 . We fused teLuc with CyOFP1 to derive Antares2, and this further improved bioluminescence detection in deep tissues. Antares2 is an excellent bioluminescent reporter when the molecular size of the reporter is not important and when CyOFP1 does not cause spectral crosstalk. Overall, our work provides several robust bioluminescent reporters, including teLuc and Antares2, which are expected to have broad applications in the fields of chemistry, biology, and biomedicine.
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acKnoWLedgments pNCS-Antares and pcDNA3-ReNL were gifts from M. Lin and T. Nagai (Addgene plasmids 74279 and 85203), respectively. We thank the University of California, Riverside, the National Institutes of Health (R01GM118675 and R21EB021651), and the National Science Foundation (CHE-1351933) for financial support. We thank T.M. Truong for reading and revising the manuscript. and n = 3 for all other groups). Unpaired two-tailed t-tests were used to compare teLuc-DTZ and Antares2-DTZ with FLuc-d-luciferin or Antares-furimazine (*1, P = 0.0015; *2, P = 0.0002; *3, P < 0.0001; *4, P = 0.0042; *5, P < 0.0001; *6, P < 0.0001), indicating the existence of a significant enhancement by teLuc and Antares2. Synthesis of diphenylterazine and selenoterazine. Methods for preparing DTZ and STZ are described in Supplementary Note 2.
Construction of plasmids and libraries. Polymerase chain reaction (PCR) with various synthetic oligonucleotide pairs (see Supplementary Table 2 ) was used to amplify all genetic elements. The gene for NanoLuc was purchased from Integrated DNA Technologies as a gBlock and further amplified with oligos XhoI-NL-F and NL-R-HindIII. The product was digested with XhoI and HindIII restriction enzymes and then ligated into a predigested, compatible pBAD/His B plasmid (Life Technologies). To create a gene library with randomization at residues 44, 54, and 138, oligo pairs XhoI-NL-F and I44I54-NNK-R, I44I54-NNK-F and I138-NNK-R, and I138-NNK-F and NL-R-HindIII were used to amplify three individual fragments from NanoLuc. The resultant three fragments were purified by agarose gel electrophoresis and used as templates for assembly in subsequent PCR reactions by using oligos XhoI-NL-F and NL-R-HindIII. The assembled full-length fragment was subsequently digested with XhoI and HindIII restriction enzymes and ligated into pBAD/His B. To create a library with randomization at residues 18, 19, 162, and 164, a similar multistep overlap PCR strategy was used. XhoI-NL-F and L18D19-NNK-R, L18D19-NNK-F and R162C164-NNK-R were used to create two fragments, which were next assembled by using XhoI-NL-F and NL-R-HindIII. The resultant gene fragment was also treated with XhoI and HindIII and ligated into a predigested pBAD/His B plasmid. To introduce random mutations across the NanoLuc gene, Taq DNA polymerase was used in all reactions with 0.2 mM MnCl 2 added to promote amplification errors. To create mammalian expression plasmids, HindIII-NL-F-Koz and NL-R-XhoI (or NL-R-164H and NL-R-164S) were used to amplify NanoLuc and NanoLuc mutants.
The products were treated with HindIII and XhoI restriction enzymes and ligated into a predigested compatible pcDNA3 plasmid (Life Technologies). The Firefly luciferase (FLuc) gene and the FLuc2 gene were amplified from a pGL2-GAL4-UASLuc plasmid (Addgene cat. no. 33020) and pGL4.17 (Promega), respectively, by using FLuc-F and FLuc-R or Luc2-F-HindIIIKozak and Luc2-Myc-R, and inserted into pcDNA3 between HindIII and XhoI sites. Ant-HindIII-F-koz and Ant-XhoI-R were used to amplify a fragment containing the Antares gene from pNCS-Antares (Addgene cat. no. 74279). The product was digested with HindIII and XhoI and then ligated into a predigested pcDNA3 plasmid as mentioned above. To replace the NanoLuc fragment in Antares with teLuc, oligo pairs AntHindIII-F-koz and Te19DtoS_R, Te19DtoS_F and Te85DtoN_R, Te85DtoN_F and Te164CtoH_R, Te164CtoH_F and Antares_ R_HindIII were used to amplify four individual fragments from pNCS-Antares. The resultant four fragments were used as templates and assembled via PCR reactions by using oligo pairs Ant-HindIII-F-koz and Ant-XhoI-R. The product was digested with HindIII and XhoI, purified by agarose gel electrophoresis, and ligated into a predigested pcDNA3 plasmid to give pcDNA3-Antares2. To construct a bacterial expression plasmid for Antares2, oligos Antares_F_XhoI and Antares_R_HindIII were used to amplify the whole gene from pcDNA3-Antares2, which was subsequently digested with XhoI and HindIII and inserted into a compatible, predigested pBAD/HisB plasmid. To construct mammalian expression plasmids with C-terminal Myc tags, the aforementioned forward primers for the construction of pcDNA3 plasmids were individually paired with NL-Myc-R, teLuc-Myc-R, yeLuc-Myc-R, FLuc-Myc-R, Luc2-Myc-R, or Antares-Myc-R to amplify the corresponding luciferase genes, which were further extended using Myc-R-XhoI paired with the corresponding forward primers. To build bicistronic plasmids containing a self-cleaving porcine teschovirus-1 P2A peptide (GSGATNFSLLKQAGDVEENPGP), oligos P2A-FLuc-F and FLuc-R were used to amplify the FLuc gene; and teLuc-P2A-R, NLuc-P2A-R, and P2A-ext-R were paired with the corresponding forward primers to amplify teLuc or NanoLuc. These fragments were further assembled using overlap PCR to create NanoLuc-P2A-FLuc or teLuc-P2A-FLuc. The products were digested with HindIII and XhoI, purified by agarose gel electrophoresis, and ligated into a predigested pcDNA3 plasmid. All ligation products were used to transform Escherichia coli DH10B electrocompetent cells, which were next plated on LB agar plates supplemented with ampicillin (100 µg/mL). Additional l-arabinose (0.02%, w/v%) was supplemented to induce protein expression for direct bioluminescence imaging of bacterial colonies.
Library screening. DH10B cells containing NanoLuc mutants were plated on LB agar plates supplemented with ampicillin (100 µg/mL) and l-arabinose (0.02%, w/v%) and incubated at 37 °C overnight to form bacterial colonies. Agar plates were left at room temperature for another 6 h, and this was followed by bioluminescence imaging using a luminescence dark box (Stanford Photonics) equipped with a Pixis 1024B CCD camera (Princeton Instruments). Digital images were acquired after spraying ~100 µL of 200 µM substrates to each agar plate, and next the images were processed with the Fiji image analysis software 21 to derive bioluminescence intensities of individual colonies. For each compound, the brightest 50 colonies from a total of ~20,000 colonies were chosen and inoculated in 5 mL liquid LB broth containing ampicillin (100 µg/mL) and l-arabinose (0.02%, w/v%). After overnight growth at 37 °C and 250 r.p.m., the cultures were moved onto a shaker at room temperature for another 6 h. Luciferase expression and purification. Luciferases were expressed and purified as His 6 -tagged fusion proteins. DH10B cells containing corresponding pBAD plasmids were grown in 5 mL LB starter cultures containing ampicillin (100 µg/mL) at 37 °C and 250 r.p.m. overnight. Each saturated overnight culture was diluted 100-fold into 2YT media containing the appropriate antibiotics and grown under the same conditions. When OD 600 reached 0.7-0.9, the expression culture was induced with larabinose (0.2%, w/v) and incubated at room temperature with shaking at 250 r.p.m. for another 16 h. Cells were harvested by centrifugation at 4,700 r.p.m. for 15 min and lysed by sonication. The resulting cell lysate was clarified by centrifugation at 18,000 r.p.m. for 30 min at 4 °C. The supernatant was incubated with Ni-NTA agarose beads (Pierce) at 4 °C for 2 h. Agarose beads loaded to a plastic column were sequentially washed with 10 mL of wash buffer 1 (pH 8.0, 50 mM Tris HCl, 20 mM Imidazole, 300 mM NaCl, 1 mM DTT) and 10 mL of wash buffer 2 (pH 8.0, 50 mM Tris HCl, 50 mM Imidazole, 300 mM NaCl, 1 mM DTT), followed by elution with elution buffer (pH 8.0, 50 mM Tris HCl, 300 mM Imidazole, 300 mM NaCl, 1 mM DTT). Proteins were buffer exchanged into Tris-HCl (50 mM, pH 7.4) containing 1 mM DTT using Thermo Scientific Snakeskin dialysis tubing and next concentrated using 3 kDa Amicon Ultra Centrifugal Filters (EMD Millipore). Protein concentrations were determined using the Pierce Coomassie Bradford Protein Assay Kit (Thermo Fisher). For storage, glycerol was added to a final concentration of 50% (v/v), and the resultant mixtures were kept at −20 °C.
In vitro bioluminescence characterization. A Synergy Mx
Microplate Reader (BioTek) was used for all in vitro bioluminescence characterizations. For kinetics measurements, no emission filter or monochromator was used. 50 µL of luciferin substrates in the assay buffer (1 mM CDTA, 0.5% Tergitol NP-40, 0.05% Antifoam 204, 150 mM KCl, 100 mM MES pH 6.0, 1 mM DTT, and 35 mM thiourea) was injected into the wells of white 96-well plates containing 50 µL of pure enzymes in the same assay buffer. The final concentrations of all enzymes and substrates were 100 pM and 30 µM, respectively. Measurements were taken every 60 s postinjection (1 s integration and 10 s shaking during intervals). FLuc bioluminescence assays were performed similarly, except the assay buffer contained 30 mM MOPS, pH 7.0, 1.5 mM ATP, and 5 mM MgSO 4 . To derive values for apparent Michaelis constants (K m ), substrate concentrations varied from 0.78 to 50 µM, and peak bioluminescence intensities at individual substrate concentrations were used to fit the Michaelis-Menten equation. To convert relative arbitrary unit (RLU) to the number of photons, the instrument was calibrated by determining the chemiluminescence of 50-800 nM luminol (QY = 1.23%) 22 in the presence of 100nM horseradish peroxidase and 2mM hydrogen peroxide in 0.1 M K 2 CO 3 aqueous solution for a total volume of 200 µL.
To determine the quantum yields of bioluminescent reactions, 0.01 nmol of each luciferin in 50 µL PBS was injected into 150 µL PBS containing 0.5 nmol of the corresponding luciferase. 1.5 mM ATP and 5 mM Mg were added to the reaction between FLuc and d-luciferin. Signals were integrated until the substrates were completely consumed. Integrated total photos were divided by the total numbers of substrate molecules to derive the quantum yields of bioluminescence reactions. The validation of our results was confirmed by measuring the quantum yields of the Renilla luciferase mutant RLuc8 in the presence of CTZ (QY = 6.9%) 23 and FLuc in the presence of d-luciferin (QY = 41 ± 7.4%) 24 . k cat values for individual enzymes were determined using the equation:
, where I max is the maximal luminescence intensity from the fitting of the Michaelis-Menten equation, and [E] is the enzyme concentration. A Tecan M1000 Pro Plate Reader was used to record emission spectra. 50 µL of individual substrates (60 µM) in assay buffers were injected into 50 µL of 2 nM pure enzymes, and the bioluminescence spectra were collected with 0.1 s integration and 1 nm increments from 400 to 750 nm.
Mammalian cell culture and transfection. HEK 293T (purchased from ATCC and tested for mycoplasma by PCR), which is one of the most widely used and readily transfectable cell lines, was used for all tissue culture transfections. HEK 293T cells were cultured at 37 °C with 5% CO 2 in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Transfection mixtures were prepared with 3 µg of plasmid DNA and 9 µg of PEI (polyethylenimine, linear, MW 25 kDa) in DMEM and incubated for 20 min at room temperature. The medium was first aspirated, and subsequently the transfection mixtures were added to cells at 70% confluency on 35 mm culture dishes seeded 1 d before transfection. Incubation lasted for 3 h at 37 °C. Fresh DMEM containing 10% FBS was next used to replace the transfection mixtures. After incubation for another 24 h at 37 °C in a CO 2 incubator, the medium was removed and cells were collected and resuspended in Dulbecco′s phosphate-buffered saline (DPBS).
Evaluation of the cytotoxicity of luciferins. Cell viability was determined using RealTime-Glo MT Cell Viability Assay (Promega) after incubation of HEK 293T cells with individual luciferin substrates for 24 h at 37 °C. Cell morphology was further evaluated using microscopy. Briefly, HEK 293T cells in 35 mm culture dishes were washed twice with 400 µL DPBS prewarmed to 37 °C and further incubated in 500 µL DPBS containing 20 µg/mL propidium iodide (PI), a fluorescent stain for dead cells, at room temperature for 15 min under light-shielded conditions. Cells were further rinsed with prewarmed 300 µL DPBS three times to remove residual PI. Cells in 300 µL DPBS were next analyzed on a Motic AE31 microscope equipped with a 100 W Short-Arc Mercury lamp, a 540/25 nm excitation filter, a 565 nm long-pass dichroic mirror, and a 605/55 nm emission filter.
Bioluminescence measurements in HEK 293T cells and cell lysates. The number and density of cells in DPBS suspension were determined using a hemocytometer. Cells were next diluted in DPBS to gain the needed numbers in each 100 µL solution. To use the luminescence dark box to directly image cells, we added luciferase-expressing HEK293T cells (2,000 cells per well with ~70% transfection efficiency) and the corresponding luciferin substrates into wells of a white-wall, 96-well plate. Bioluminescence was imaged using a Pixis 1024B cooled CCD camera equipped with a 50-mm f/0.95 lens at 1 m post-substrate addition. The camera exposure time was 1 s, and the field of view was 6 × 6 inches. A 695BP50 (Omega Optical) filter was used to acquire far-red emission. All images were analyzed using the Fiji image analysis software 21 . Cell lysates were prepared by sonication. Without further separation, luciferin substrates in 100 µL assay buffers were added to initiate bioluminescence reactions.
Western blot. To examine the protein levels of tested luciferases in mammalian cells, we transfected HEK 293T cells with mammalian expression plasmids harboring C-terminal, c-Myc-tagged luciferase genes. Cell lysates were prepared using CelLytic M Cell Lysis Buffer (Sigma-Aldrich) supplemented with cOmplete Protease Inhibitor Cocktail (Promega). Cell lysates were clarified by centrifugation at 14,000× g for 10 min. The Bradford assay was used to determine total protein concentrations in the lysates. 10 µg of total proteins were loaded to each lane and resolved on a 12% SDS-PAGE gel. Proteins were next transferred to a nitrocellulose membrane at 40 V for 3 h. The membrane was blocked with 5% bovine serum albumin (BSA) in 1× PBS with Tween 20 (PBST) for 1 h and then incubated with either an anti-c-Myc (Santa Cruz Biotechnology, sc-40; 1:3,000 dilution) or an anti-β-actin antibody (ThermoFisher Scientific, PA1-183; 1:10,000 dilution) in PBST containing 3% BSA at 4 °C overnight. After washing four times with PBST, the corresponding horseradish peroxidase (HRP) conjugated secondary antibodies (goat antimouse IgG, ThermoFisher Scientific, 31430; or goat anti-rabbit IgG, Sigma-Aldrich, A0545; both at 1:10,000 dilution) were added and incubated for 1 h at room temperature. Membranes were visualized with Amersham ECL Western Blotting Detection Reagent (GE Healthcare) on a Bio-Rad Gel Doc XR System.
Bioluminescence imaging of HEK 293T cells at superficial sites on live mice. BALB/c mice on a 37 °C electronic heat pad were anesthetized using 2% isoflurane in 100% oxygen with a flow of 0.5 l/min. We subcutaneously injected 2 million HEK 293T cells transfected with luciferase genes and resuspended in 100 µL PBS into the right dorsolateral trapezius region of unshaved BALB/c mice; and we transfected another 2 million cells with an empty vehicle vector, resuspended them in 100 µL PBS, and injected them into the left dorsolateral thoracolumbar region. After cells were settled for 5 min, the corresponding luciferase substrates with indicated concentrations in 100 µL PBS were also subcutaneously injected to each site. Mice were subsequently imaged with a 30 s exposure per frame for a total of 5 min using a luminescence dark box (Stanford Photonics) equipped with a Pixis 1024B cooled CCD camera. The Fiji image analysis software 21 was used to analyze images and integrate bioluminescence intensities over common regions of interest encompassing all injected cells.
Bioluminescence imaging in deep tissues of live mice.
Hydrodynamic transfections were performed on BALB/c mice as described elsewhere 25 . Briefly, 20 µg of each luciferase-expressing plasmid in sterilized saline (volume equivalent to 9% bodyweight of the treated mouse) was injected into restrained mice via the tail vein over 4-8 s. Mice were allowed to recover on heat pads and were monitored until their breathing rate returned to normal. Bioluminescence images were acquired at 12 h postinjection. d-luciferin or AkaLumine-HCl at the indicated dose was dissolved in 100 µL PBS and intraperitoneally injected into FLuctransfected mice. Prior to intraperitoneal injections of CTZ analogs to teLuc, Antares, or Antares2-transfected mice, the indicated dose of DTZ or furimazine was dissolved in a 100 µL solution containing 8% glycerol, 10% ethanol, 10% hydroxypropyl -β-cyclodextrin, and 35% PEG 400 in water. To inject 3.3 µmol DTZ or furimazine, the total volumes were increased to 500 µL. The luminescence dark box (Stanford Photonics) equipped with a Pixis 1024B cooled CCD camera was again used to image anesthetized mice with a 1 min exposure per frame over a course of 10 min. The Fiji image analysis software 21 was used to process images and derive integrated intensities. 
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